C-MER MEDICAL (03309) announced its full-year financial results for the fiscal period ending December 31, 2025. The group reported revenue of HK$1.947 billion, representing a year-on-year increase of 1.8%. Shareholders’ attributable profit was HK$100 million, marking a turnaround from a loss in the previous year. Earnings per share stood at HK8.33 cents, and a final dividend of HK2 cents per share was declared.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments